Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Mucopolysaccharidosis Type VI

Metabolic & Lysosomal

Mucopolysaccharidosis Type VI (MPS VI) Clinical Trials

Also called MPS VI, Maroteaux-Lamy Syndrome, Maroteaux-Lamy

Mucopolysaccharidosis Type VI is caused by mutations in the ARSB gene, resulting in deficiency of the enzyme arylsulfatase B (also called N-acetylgalactosamine-4-sulfatase). This enzyme is needed to break down dermatan sulfate and chondroitin 4-sulfate, glycosaminoglycans found throughout connective tissues. Without it, these substrates accumulate in lysosomes, progressively damaging bones, joints, heart valves, corneas, and other organs.

In plain words, MPS VI happens when a gene change leaves the body without an enzyme that breaks down certain sugar chains. These build up in the bones, joints, heart valves and eyes but usually leave thinking and learning unaffected.

Get an email when new Mucopolysaccharidosis Type VI trials open or the FDA decides. Get alerts

Mucopolysaccharidosis Type VI

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Naglazyme

Mucopolysaccharidosis Type VI has 1 FDA-approved medicine, 3 open or active clinical trials (3 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Mucopolysaccharidosis Type VI

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Mucopolysaccharidosis Type VI

The disease has a wide clinical spectrum. The severe, rapidly progressing form causes significant skeletal deformity, cardiac disease, and respiratory compromise that can be life-threatening by the second or third decade. Milder forms progress more slowly but still cause cumulative organ damage over time.

Keep reading about Mucopolysaccharidosis Type VI

Naglazyme (galsulfase), an enzyme replacement therapy developed by BioMarin and FDA-approved in 2005, is administered as a weekly intravenous infusion and has been shown to improve walking capacity and stair-climbing ability. Early treatment before significant organ damage has occurred leads to the best outcomes, which has driven interest in including MPS VI in newborn screening programs.

What are the symptoms of Mucopolysaccharidosis Type VI?

These are common symptoms of Mucopolysaccharidosis Type VI, and how strong they are varies from person to person.

  • Short stature and progressive growth failure
  • Joint stiffness and contractures limiting mobility
  • Coarse facial features that become more prominent with age
  • Corneal clouding and progressive vision loss
  • Heart valve abnormalities including stenosis and regurgitation
  • Carpal tunnel syndrome with hand numbness and weakness
  • Cervical spinal stenosis with risk of spinal cord compression
  • Enlarged liver and spleen (hepatosplenomegaly)
  • Progressive hearing loss and recurrent ear infections
  • Respiratory compromise from chest wall deformity and airway obstruction

Who gets Mucopolysaccharidosis Type VI?

Severe forms present in early childhood (ages 2-3) with rapid progression, while milder forms may not be recognized until late childhood or adolescence.

Severe cases can be life-threatening by the teens or twenties; milder forms allow survival into adulthood with reduced life expectancy. Affects males and females equally. Autosomal recessive inheritance requiring mutations in both copies of the ARSB gene. Intelligence is normal, distinguishing MPS VI from several other MPS types.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Mucopolysaccharidosis Type VI?

There is currently 1 FDA-approved medication for Mucopolysaccharidosis Type VI.

galsulfase
BioMarin Pharmaceutical Inc.
Official site

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Mucopolysaccharidosis Type VI treatment

Charity funds and drugmaker programs for Mucopolysaccharidosis Type VI, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    MPS VI Medical Assistance fund
    Open

    Pays for: Medical and medication costs.

    The foundation says: “Accepting new applications and re-enrollments for current year”
  • From a charity · NORD RareCare
    MPS VI Premium Copay Assistance fund
    Open

    Pays for: Insurance premiums and copays.

    The foundation says: “Accepting new applications and re-enrollments for current year”
  • From a charity · NORD RareCare
    Mucopolysaccharidosis type VI (MPS VI) Emergency Relief fund
    Open

    Pays for: Emergency relief.

    The foundation says: “Accepting Applications”
  • From a charity · National MPS Society
    Family Assistance Program fund
    Apply directly

    Pays for: Specialized equipment and medical aids not covered by insurance (requires insurance denial and 10% family copay), up to $3,000 per year.

    The foundation says: “Status not shown on page”
  • From a charity · National MPS Society
    Medical Travel Assistance Program fund
    Apply directly

    Pays for: Travel to out-of-town medical appointments more than 125 miles away (per year), up to $550 per year.

    The foundation says: “Status not shown on page”
  • From a charity · National MPS Society
    Journey Assistance Program fund
    Apply directly

    Pays for: Items that ease daily life (40% of purchase price), up to $500 per year.

    The foundation says: “Status not shown on page”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Mucopolysaccharidosis Type VI, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Mucopolysaccharidosis Type VI

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Mucopolysaccharidosis Type VI resources

Reputable organizations and medical references for learning more about Mucopolysaccharidosis Type VI, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Mucopolysaccharidosis Type VI

Use this Mucopolysaccharidosis Type VI clinical trial finder to see the 3 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenNo updates in a whileNCT05619900

Registry of Patients Diagnosed With Lysosomal Storage Diseases

Intervention: There is no intervention

Sponsor: University of California, San Francisco

This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.

Ages up to 64 Years1 location
Started May 2022Updated 7 months agoEst. May 2050 (~23y 6m)
RecruitingTreatment trialPhase 1No updates in a whileNCT04532047

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Intervention: Aldurazyme (laronidase)

Sponsor: University of California, San Francisco

For detailed information, please view our study website: https://pearltrial.ucsf.edu/

The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.

Ages 18 Years to 50 Years1 location
Started Jul 2021Updated 8 months agoEst. Jul 2031 (~4y 8m)
RecruitingObservational study, no treatment givenNo updates in a whileNCT06036693

MPS (RaDiCo Cohort) (RaDiCo-MPS)

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.

Ages not specified
Started Dec 2017Updated 9 months agoEst. Dec 2026 (~1 month)
Find Mucopolysaccharidosis Type VI trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Mucopolysaccharidosis Type VI trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Mucopolysaccharidosis Type VI foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Mucopolysaccharidosis Type VI patient communities

Facebook groups, Reddit communities and YouTube channels where Mucopolysaccharidosis Type VI patients, caregivers and advocacy groups talk.

Companies developing Mucopolysaccharidosis Type VI treatments

Drugmakers that list Mucopolysaccharidosis Type VI in their rare disease portfolio, 1 in all.

Questions people ask about Mucopolysaccharidosis Type VI